Sym-023 is under clinical development by Les Laboratoires Servier and currently in Phase I for Metastatic Bile Duct Cancer. According to GlobalData, Phase I drugs for Metastatic Bile Duct Cancer have a 92% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Sym-023’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sym-023 overview
Sym-023 is under development for the treatment of advanced/ unresectable or metastatic solid tumor malignancies and lymphomas, bile duct cancer (cholangiocarcinoma), advanced or metastatic esophageal squamous cell carcinoma, metastatic biliary tract carcinoma including adenocarcinoma of the intra- and/or extra-hepatic bile ducts,metastatic bile duct cancer, non-small cell lung cancer and gallbladder carcinoma. It is administered through intravenous route. It is a recombinant, fully human monoclonal antibody (mAb). The drug candidate acts by targeting TIM-3. It is developed based on sympress platform technology.
It was under development for the treatment of small-cell lung cancer, cholangiocarcinoma, small-cell lung cancer, urothelial cell cancer, endometrial cancer.
Les Laboratoires Servier overview
Les Laboratoires Servier (Servier) researches, develops, manufactures, and markets drugs for treating various diseases. The company’s portfolio of marketed products treats central nervous system (CNS) disorders, cardiovascular diseases, cancer, ENT disorders, respiratory diseases, hematological disorders, hormonal disorders, and others. The company also provides generic drugs and contract development and manufacturing services across its global network. The company also provides digital therapeutic solutions through its e-health division, WeHealth Digital Medicine. It sells products in Europe, America, Middle East, Africa, and Asia. Servier headquartered in Suresnes, Ile-de-France, France.
For a complete picture of Sym-023’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
